The members of the management of Diamyd, Inc. entered into an agreement to acquire 90% stake in Diamyd Inc. from Diamyd Medical AB (OM:DIAM B) for $10 million on October 8, 2012. The purchase price consists of $1 in cash. Additionally, Diamyd Medical may receive up to $10 million, primarily in milestone payments, as well as 10% of upfront payments and other payments management may receive from future partners, and royalties on future sales of NTDDS based drugs. Under the agreement, in addition to the shares in Diamyd, Inc., the management will assume the intellectual property rights to the patented Nerve Targeting Drug Delivery System (NTDDS) technology and all costs and revenues related to the business.

The agreement is subject to approval from Diamyd Medical's shareholders at an extraordinary general meeting to be held on October 30, 2012. As of October 30, 2012, Diamyd Medical's shareholders approved the transaction.

The members of the management of Diamyd, Inc. cancelled the acquisition of 90% stake in Diamyd Inc. from Diamyd Medical AB (OM:DIAM B) on October 8, 2013.